Cover Image
Market Research Report

North America Anti-Nuclear antibody test Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025

Published by Data Bridge Market Research Private Limited Product code 610295
Published Content info 248 Pages
Delivery time: 1-2 business days
Price
Back to Top
North America Anti-Nuclear antibody test Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025
Published: February 18, 2018 Content info: 248 Pages
Description

North America anti-nuclear antibody test market is expected to reach USD 920.96 million by 2025 from USD 520.46 million in 2017, at a CAGR of 7.5% in the forecast period 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

The major factors driving the growth of this market are increasing incidence of autoimmune diseases, rising medical insurance, and rise in government healthcare protection.

The key market players for North America anti-nuclear antibody test market are listed below:

  • Bio-Rad Laboratories, Inc.
  • Alere, Inc.
  • Trinity Biotech
  • Thermo Fisher Scientific Inc.
  • Antibodies Inc.
  • EUROIMMUN AG
  • Immuno Concepts

The market is further segmented into:

  • Product
  • Test
  • Disease
  • End-user

The North America anti-nuclear antibody test market is segmented on the basis of product into assay kits & reagents, systems, and software. In 2018, assay kits & reagents is expected to dominate the North America anti-nuclear antibody test market with 52.0% market share and is expected to reach USD 485.67 million by 2025, with the highest CAGR of 7.7% in the forecast period 2018 to 2025.

The North America anti-nuclear antibody test market is segmented on the basis of test into indirect immunofluorescence, ELISA, and multiplex testing. In 2018, indirect immunofluorescence is expected to dominate the North America anti-nuclear antibody test market with 46.0% market share and is expected to reach USD 394.83 million by 2025, with the CAGR of 6.4% in the forecast period 2018 to 2025. However, multiplex testing market segment is expected to grow at the highest CAGR of 8.8% in the forecast period, and is expected to reach USD 230.71 million in 2025 from USD 118.06 million in 2017.

The North America anti-nuclear antibody test market is segmented on the basis of disease into systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, scleroderma, polymyositis, and others. In 2018, systemic lupus erythematosus is expected to dominate the North America anti-nuclear antibody test market with 28.2% market share and is expected to reach USD 275.94 million by 2025, with the highest CAGR of 8.5% in the forecast period 2018 to 2025.

The North America anti-nuclear antibody test market is segmented on the basis of end-user into hospitals, clinics, physician office laboratories, and others. In 2018, hospitals is expected to dominate the North America anti-nuclear antibody test market with 47.3% market share and is expected to reach USD 443.42 million by 2025, with the highest CAGR of 7.8% in the forecast period 2018 to 2025.

Based on geography, the North America anti-nuclear antibody test market is segmented into geographical regions, such as,

  • U.S.
  • Canada
  • Mexico

Covered in this report:

The report covers the present scenario and the growth prospects of the North America anti-nuclear antibody test for 2018-2025. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. OVERVIEW OF NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET
  • 1.4. CURRENCY AND PRICING
  • 1.5. LIMITATION
  • 1.6. MARKETS COVERED

2. MARKET SEGMENTATION

  • 2.1. MARKETS COVERED
  • 2.2. GEOGRAPHIC SCOPE
  • 2.3. YEARS CONSIDERED FOR THE STUDY
  • 2.4. CURRENCY AND PRICING
  • 2.5. RESEARCH METHODOLOGY
  • 2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.7. SECONDARY SOURCES
  • 2.8. ASSUMPTIONS

3. MARKET OVERVIEW

  • 3.1. DRIVERS
    • 3.1.1. INCREASING INCIDENCE OF AUTOIMMUNE DISEASES
    • 3.1.2. RISING MEDICAL INSURANCE
    • 3.1.3. RISE IN GOVERNMENT HEALTHCARE PROTECTION
  • 3.2. RESTRAINTS
    • 3.2.1. STRICT REGULATION FOR PRODUCT APPROVAL
  • 3.3. OPPORTUNITIES
    • 3.3.1. INCREASING GROWTH IN HEALTHCARE EXPENDITURE
    • 3.3.2. EMERGING MARKETS
    • 3.3.3. LABORATORY AUTOMATION FAVORS THE MARKET
  • 3.4. CHALLENGES
    • 3.4.1. LACK OF SKILLED PROFESSIONALS

4. EXECUTIVE SUMMARY

5. PREMIUM INSIGHTS

6. NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT

  • 6.1. OVERVIEW
  • 6.2. ASSAY KITS & REAGENTS
  • 6.3. SYSTEMS
  • 6.4. SOFTWARE

7. NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST

  • 7.1. OVERVIEW
  • 7.2. INDIRECT IMMUNOFLUORESCENCE
  • 7.3. ELISA
  • 7.4. MULTIPLEX TESTING

8. NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE

  • 8.1. OVERVIEW
  • 8.2. RHEUMATOID ARTHRITIS
  • 8.3. SYSTEMIC LUPUS ERYTHEMATOSUS
  • 8.4. SJOGREN'S SYNDROME
  • 8.5. SCLERODERMA
  • 8.6. POLYMYOSITIS
  • 8.7. OTHERS

9. NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER

  • 9.1. OVERVIEW
  • 9.2. HOSPITALS
  • 9.3. CLINICS
  • 9.4. PHYSICIAN OFFICE LABORATORIES
  • 9.5. OTHERS

10. NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY GEOGRAPHY

  • 10.1. OVERVIEW
  • 10.2. NORTH AMERICA
    • 10.2.1. U.S.
    • 10.2.2. CANADA
    • 10.2.3. MEXICO

11. NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET,

COMPANY LANDSCAPE 220

  • 11.1. COMPANY SHARE ANALYSIS: NORTH-AMERICA
  • 11.2. COMPANY SHARE ANALYSIS: NORTH AMERICA
  • 11.3. COMPANY SHARE ANALYSIS: EUROPE
  • 11.4. COMPANY SHARE ANALYSIS: ASIA PACIFIC

12. COMPANY PROFILES

  • 12.1. THERMO FISHER SCIENTIFIC INC.
    • 12.1.1. COMPANY OVERVIEW
    • 12.1.2. THERMO FISHER SCIENTIFIC INC.:REVENUE ANALYSIS
    • 12.1.3. PRODUCT PORTFOLIO
    • 12.1.4. RECENT DEVELOPMENTS
  • 12.2. MERCK KGAA
    • 12.2.1. COMPANY OVERVIEW
    • 12.2.2. MERCK KGAA: REVENUE ANALYSIS
    • 12.2.3. PRODUCT PORTFOLIO
    • 12.2.4. RECENT DEVELOPMENTS
  • 12.3. ALERE INC.
    • 12.3.1. COMPANY OVERVIEW
    • 12.3.2. ALERE INC.: REVENUE ANALYSIS
    • 12.3.3. PRODUCT PORTFOLIO
    • 12.3.4. RECENT DEVELOPMENTS
  • 12.4. TRINITY BIOTECH
    • 12.4.1. COMPANY OVERVIEW
    • 12.4.2. TRINITY BIOTECH: COMPANY OVERVIEW
    • 12.4.3. PRODUCT PORTFOLIO
    • 12.4.4. RECENT DEVELOPMENTS
  • 12.5. ANTIBODIES INC.
    • 12.5.1. COMPANY OVERVIEW
    • 12.5.2. ANTIBODIES INC.: REVENUE ANALYSIS
    • 12.5.3. PRODUCT PORTFOLIO
    • 12.5.4. RECENT DEVELOPMENTS
  • 12.6. BIO-RAD LABORATORIES, INC.
    • 12.6.1. COMPANY OVERVIEW
    • 12.6.2. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
    • 12.6.3. PRODUCT PORTFOLIO
    • 12.6.4. RECENT DEVELOPMENTS
  • 12.7. EUROIMMUN AG (A SUBSIDIARY OF PERKINELMER INC.)
    • 12.7.1. COMPANY OVERVIEW
    • 12.7.2. PERKINELMER INC.: REVENUE ANALYSIS
    • 12.7.3. PRODUCT PORTFOLIO
    • 12.7.4. RECENT DEVELOPMENTS
  • 12.8. IMMUNO CONCEPTS
    • 12.8.1. COMPANY OVERVIEW
    • 12.8.2. IMMUNO CONCEPTS: COMPANY SNAPSHOT
    • 12.8.3. PRODUCT PORTFOLIO
    • 12.8.4. RECENT DEVELOPMENTS

  • 12.9. INOVA DIAGNOSTICS
    • 12.9.1. COMPANY OVERVIEW
    • 12.9.2. INOVA DIAGNOSTICS:COMPANY SNAPSHOT
    • 12.9.3. PRODUCT PORTFOLIO
    • 12.9.4. RECENT DEVELOPMENTS
  • 12.10. ZEUS SCIENTIFIC, INC.
    • 12.10.1. COMPANY OVERVIEW
    • 12.10.2. ZEUS SCIENTIFIC, INC.: COMPANY SNAPSHOT
    • 12.10.3. PRODUCT PORTFOLIO
    • 12.10.4. RECENT DEVELOPMENTS
  • 12.11. MBL INTERNATIONAL
    • 12.11.1. COMPANY OVERVIEW
    • 12.11.2. MBL INTERNATIONAL: COMPANY SNAPSHOT
    • 12.11.3. PRODUCT PORTFOLIO
    • 12.11.4. RECENT DEVELOPMENTS
  • 12.12. MEDSOURCE OZONE BIOMEDICALS PVT. LTD
    • 12.12.1. COMPANY OVERVIEW
    • 12.12.2. MEDSOURCE OZONE BIOMEDICALS PVT. LTD: COMPANY SNAPSHOT
    • 12.12.3. PRODUCT PORTFOLIO
    • 12.12.4. RECENT DEVELOPMENTS
  • 12.13. AESKU GROUP GMBH & CO. KG
    • 12.13.1. COMPANY OVERVIEW
    • 12.13.2. AESKU GROUP GMBH & CO. KG: COMPANY SNAPSHOT
    • 12.13.3. PRODUCT PORTFOLIO
    • 12.13.4. RECENT DEVELOPMENTS

13. RELATED REPORTS

LIST OF TABLES

TABLE LIST

TABLE 1 PREVALENCE OF FEW AUTOIMMUNE DISEASESIN U.S. (2012) 37

TABLE 2 PROJECT FUNDING FOR RHEUMATOID ARTHRITIS AND LUPUS

(2018-2023) (USD MILLION) 39

TABLE 3 HEALTHCARE EXPENDITURE IN ASIA PACIFIC (USD MILLION) 42

TABLE 4 NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET , BY PRODUCT,

2016 - 2025 (USD MILLION) 57

TABLE 5 NORTH-AMERICA ASSAY KITS & REAGENTS MARKET, BY REGION,

2016 - 2025 (USD MILLION) 58

TABLE 6 NORTH-AMERICA SYSTEMS MARKET, BY REGION, 2016 - 2025 (USD MILLION) 59

TABLE 7 NORTH-AMERICA SOFTWARES MARKET, BY REGION, 2016 - 2025 (USD MILLION) 60

TABLE 8 NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST,

2016 - 2025 (USD MILLION) 63

TABLE 9 NORTH-AMERICA INDIRECT IMMUNOFLUORESCENCE MARKET, BY REGION,

2016 - 2025 (USD MILLION) 64

TABLE 10 NORTH-AMERICA ELISA MARKET, BY REGION, 2016 - 2025 (USD MILLION) 65

TABLE 11 NORTH-AMERICA MULTIPLEX TESTING MARKET, BY REGION,

2016 - 2025 (USD MILLION) 66

TABLE 12 NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET , BY DISEASE,

2016 - 2025 (USD MILLION) 69

TABLE 13 NORTH-AMERICA RHEUMATOID ARTHRITIS MARKET, BY REGION,

2016 - 2025 (USD MILLION) 70

TABLE 14 NORTH-AMERICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, BY REGION,

2016 - 2025 (USD MILLION) 71

TABLE 15 NORTH-AMERICA SJOGREN'S SYNDROME MARKET, BY REGION,

2016 - 2025 (USD MILLION) 72

TABLE 16 NORTH-AMERICA SCLERODERMA MARKET, BY REGION,

2016 - 2025 (USD MILLION) 73

TABLE 17 NORTH-AMERICA POLYMYOSITIS MARKET, BY REGION, 2016 - 2025 (USD MILLION) 74

TABLE 18 NORTH-AMERICA OTHERS MARKET, BY REGION, 2016 - 2025 (USD MILLION) 75

TABLE 19 NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET , BY END USER,

2016 - 2025 (USD MILLION) 78

TABLE 20 NORTH-AMERICA HOSPITALS MARKET, BY REGION, 2016 - 2025 (USD MILLION) 79

TABLE 21 NORTH-AMERICA CLINICS MARKET, BY REGION, 2016 - 2025 (USD MILLION) 80

TABLE 22 NORTH-AMERICA PHYSICIAN OFFICE LABORATORIES MARKET, BY REGION,

2016 - 2025 (USD MILLION) 81

TABLE 23 NORTH-AMERICA OTHERS MARKET, BY REGION, 2016 - 2025 (USD MILLION) 82

TABLE 24 NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY REGION,

2016 - 2025 (USD MILLION) 90

TABLE 25 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY COUNTRY, 2016-2025 (USD MILLION) 97

TABLE 26 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 97

TABLE 27 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 98

TABLE 28 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 99

TABLE 29 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 100

TABLE 30 U.S. ANTI-NUCLEAR ANTIBODY TEST MARKET , BY PRODUCT,

2016 - 2025 (USD MILLION) 101

TABLE 31 U.S. ANTI-NUCLEAR ANTIBODY TEST MARKET , BY TEST,

2016 - 2025 (USD MILLION) 101

TABLE 32 U.S. ANTI-NUCLEAR ANTIBODY TEST MARKET , BY DISEASE,

2016 - 2025 (USD MILLION) 102

TABLE 33 U.S. ANTI-NUCLEAR ANTIBODY TEST MARKET , BY END USER,

2016 - 2025 (USD MILLION) 103

TABLE 34 CANADA ANTI-NUCLEAR ANTIBODY TEST MARKET , BY PRODUCT,

2016 - 2025 (USD MILLION) 104

TABLE 35 CANADA ANTI-NUCLEAR ANTIBODY TEST MARKET , BY TEST,

2016 - 2025 (USD MILLION) 104

TABLE 36 CANADA ANTI-NUCLEAR ANTIBODY TEST MARKET , BY DISEASE,

2016 - 2025 (USD MILLION) 105

TABLE 37 CANADA ANTI-NUCLEAR ANTIBODY TEST MARKET , BY END USER,

2016 - 2025 (USD MILLION) 106

TABLE 38 MEXICO ANTI-NUCLEAR ANTIBODY TEST MARKET , BY PRODUCT,

2016 - 2025 (USD MILLION) 107

TABLE 39 MEXICO ANTI-NUCLEAR ANTIBODY TEST MARKET , BY TEST,

2016 - 2025 (USD MILLION) 107

TABLE 40 MEXICO ANTI-NUCLEAR ANTIBODY TEST MARKET , BY DISEASE,

2016 - 2025 (USD MILLION) 108

TABLE 41 MEXICO ANTI-NUCLEAR ANTIBODY TEST MARKET , BY END USER,

2016 - 2025 (USD MILLION) 109

LIST OF FIGURES

FIGURES LIST

FIGURE 1 NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET: SEGMENTATION 27

FIGURE 2 NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET: DATA TRIANGULATION 30

FIGURE 3 NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET : RESEARCH SNAPSHOT 31

FIGURE 4 NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET : BOTTOM UP APPROACH 32

FIGURE 5 NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET: TOP DOWN APPROACH 32

FIGURE 6 NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET :

INTERVIEW DEMOGRAPHICS 33

FIGURE 7 NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET : SEGMENTATION 46

FIGURE 8 NORTH AMERICA IS EXPECTED TO DOMINATE THE MARKET FOR ANTI-NUCLEAR ANTIBODY TEST AND ASIA PACIFIC IS EXPECTED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD FROM 2018 TO 2025 47

FIGURE 9 NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET: BY PRODUCT TYPE, 2017 56

FIGURE 10 NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET: BY TEST, 2017 62

FIGURE 11 NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET: BY DISEASE, 2017 68

FIGURE 12 NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET: BY END USER, 2017 77

FIGURE 13 NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET SNAPSHOT (2017) 85

FIGURE 14 NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET: BY GEOGRAPHY (2017) 86

FIGURE 15 NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET: BY GEOGRAPHY (2018) 87

FIGURE 16 NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET: BY COUNTRY (2017 & 2025) 88

FIGURE 17 NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET:

BY PRODUCT TYPE (2018 & 2025) 89

FIGURE 18 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET: SNAPSHOT (2017) 92

FIGURE 19 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET:

BY COUNTRY (2017) 93

FIGURE 20 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET :

BY COUNTRY (2018 & 2025) 94

FIGURE 21 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY COUNTRY (2018 & 2025) 95

FIGURE 22 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY PRODUCT (2018 & 2025) 96

FIGURE 23 NORTH-AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET: COMPANY SHARE 2017 (%) 220

FIGURE 24 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET:

COMPANY SHARE 2017 (%) 221

Back to Top